Showing results (471-480 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|March 1, 2025
Prevalence, incidence, patient characteristics, and treatment trends of valvular heart disease using the national database of health insurance claims of JapanAtaru Igarashi, Tomomi Takeshima, Shoichi Irie, et al.Journal of Medical Economics|February 20, 2025
The indirect costs and burden of vaccine-preventable cancers premature mortality in Asia-Pacific countriesGoran Bencina, Manoj Gambhir, Isaya Sukarom, et al.Journal of Medical Economics|November 13, 2024
Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United StatesAlon Yehoshua, Manuela Di Fusco, Abby E Rudolph, et al.Journal of Medical Economics|November 8, 2024
Employment status of multiple sclerosis patients in JapanIchiro Nakashima, Nozomu TanakaJournal of Medical Economics|November 4, 2024
Clinical and economic benefits of patients undergoing lobectomy with the use of powered vascular staplers-based on China's real-world dataBinbin Chen, Changsheng Fan, Libo Tao, et al.Journal of Medical Economics|November 29, 2024
The burden of venous thromboembolism in ten countries: a cost-of-illness Markov model on surgical and ICU patientsKim Seemann, Ubong Silas, Antonia Bosworth Smith, et al.Journal of Medical Economics|November 29, 2024
Repeat cardiovascular-related procedures and real-world treatment in high-risk patients with hypercholesterolemia or mixed dyslipidemiaMichael Lehrke, Sabrina Müller, Ulf Maywald, et al.Journal of Medical Economics|March 10, 2025
Adverse consequences of systemic corticosteroids use among a broad population of US adults with asthma: a real-world analysisSandra Sze-Jung Wu, Michelle Vu, Omar Motawakel, et al.Journal of Medical Economics|October 10, 2024
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysisDolores Isla, Rosa Álvarez, María Arnal, et al.Journal of Medical Economics|October 16, 2024
Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in SwitzerlandNadine Schur, Andrea Favre-Bulle, Michael Flori, et al.Pageof 241